BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21258184)

  • 1. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].
    Kitamura K; Nakano Y; Watamoto K; Koga D; Naoe T
    Rinsho Ketsueki; 2010 Dec; 51(12):1748-55. PubMed ID: 21258184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
    Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
    Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
    Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia.
    Osborne D; Frost L; Tobal K; Liu Yin JA
    Bone Marrow Transplant; 2005 Jul; 36(1):67-70. PubMed ID: 15908982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients.
    Cilloni D; Gottardi E; De Micheli D; Serra A; Volpe G; Messa F; Rege-Cambrin G; Guerrasio A; Divona M; Lo Coco F; Saglio G
    Leukemia; 2002 Oct; 16(10):2115-21. PubMed ID: 12357365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.
    Kitamura K; Nishiyama T; Ishiyama K; Miyawaki S; Miyazaki K; Suzuki K; Masaie H; Okada M; Ogawa H; Imai K; Kiyoi H; Naoe T; Yokoyama Y; Chiba S; Hata T; Miyazaki Y; Hatta Y; Takeuchi J; Nannya Y; Kurokawa M; Ueda Y; Koga D; Sugiyama H; Takaku F
    Int J Hematol; 2016 Jan; 103(1):53-62. PubMed ID: 26520650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.
    Ommen HB; Nyvold CG; Braendstrup K; Andersen BL; Ommen IB; Hasle H; Hokland P; Ostergaard M
    Br J Haematol; 2008 Jun; 141(6):782-91. PubMed ID: 18410450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of detecting WT1 expression in childhood acute leukemias.
    Hu SY; Gu WY; Chen ZX; Wang XL; Cen JN; He HL; Chai YH; Chen CS
    Pediatr Hematol Oncol; 2010 Nov; 27(8):581-91. PubMed ID: 20863155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation.
    Gray JX; McMillen L; Mollee P; Paul S; Lane S; Bird R; Gill D; Saal R; Marlton P
    Leuk Res; 2012 Apr; 36(4):453-8. PubMed ID: 21967832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.